90 related articles for article (PubMed ID: 38612503)
1. Derivatives of D(-) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-I: Synthesis, biological screening and in silico binding interaction analysis.
Das S; Mondal S; Patel T; Himaja A; Adhikari N; Banerjee S; Baidya SK; De AK; Gayen S; Ghosh B; Jha T
Eur J Med Chem; 2024 Jun; 274():116563. PubMed ID: 38843586
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
3. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with
Lai HR; Wu QM; Yang YZ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720
[No Abstract] [Full Text] [Related]
4. FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5.
Takeda K; Ohta S; Nagao M; Kobayashi E; Tago K; Funakoshi-Tago M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612503
[TBL] [Abstract][Full Text] [Related]
5. Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.
Sumi K; Tago K; Nakazawa Y; Takahashi K; Ohe T; Mashino T; Funakoshi-Tago M
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054935
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
7. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
[TBL] [Abstract][Full Text] [Related]
8. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
9. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
10. A helicase-independent role of DHX15 promotes MYC stability and acute leukemia cell survival.
Li Q; Guo H; Xu J; Li X; Wang D; Guo Y; Qing G; Van Vlierberghe P; Liu H
iScience; 2024 Jan; 27(1):108571. PubMed ID: 38161423
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin.
Chang WH; Liu Y; Hammes EA; Bryant KL; Cerione RA; Antonyak MA
J Biol Chem; 2023 Feb; 299(2):102842. PubMed ID: 36581205
[TBL] [Abstract][Full Text] [Related]
12. The indispensable role of the RNA helicase DDX5 in tumorigenesis induced by the myeloproliferative neoplasm-associated JAK2V617F mutant.
Takeda K; Tago K; Funakoshi-Tago M
Cell Signal; 2023 Feb; 102():110537. PubMed ID: 36442590
[TBL] [Abstract][Full Text] [Related]
13. Identification of DDX5 as an indispensable activator of the glucocorticoid receptor in adipocyte differentiation.
Hokimoto S; Funakoshi-Tago M; Tago K
FEBS J; 2023 Feb; 290(4):988-1007. PubMed ID: 36071319
[TBL] [Abstract][Full Text] [Related]
14. Verbascoside potentiates the effect of tyrosine kinase inhibitors on the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling pathway in chronic myeloid leukaemia.
Akgun-Cagliyan G; Cort-Donmez A; Kilic-Toprak E; Altintas F
Exp Ther Med; 2022 Aug; 24(2):514. PubMed ID: 35837042
[TBL] [Abstract][Full Text] [Related]
15. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
